A preliminary report on spinal muscular atrophy lymphoblastoid cell lines: Are they an appropriate tool for drug screening?

Advances in Therapy

Volumn 25, Issue 3, 2008, Pages 274-279

  Dayangaç Erden, Didem ^a   Topaloǧlu, Haluk ^a   Erdem Yurter, Hayat ^a  

^a HACETTEPE UNIVERSITY   (Turkey)

Author keywords

Histone deacetylase inhibitors; Lymphoblastoid cell lines; Phenylbutyrate; Survival motor neuron gene; Therapy

Indexed keywords

ARYLBUTYRIC ACID DERIVATIVE; HISTONE DEACETYLASE INHIBITOR; MESSENGER RNA; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 1; SURVIVAL MOTOR NEURON PROTEIN 2;

ADULT; ARTICLE; CASE REPORT; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG SCREENING; EPSTEIN BARR VIRUS; EXON; GENE DELETION; HUMAN; HUMAN CELL; INCUBATION TIME; LYMPHOBLASTOID CELL LINE; MALE; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; REPEATED DRUG DOSE; SPINAL MUSCULAR ATROPHY; VIRUS CELL TRANSFORMATION; WALKING DIFFICULTY; WESTERN BLOTTING;

ADULT; CELL LINE, TRANSFORMED; CHILD; DRUG EVALUATION, PRECLINICAL; HERPESVIRUS 4, HUMAN; HISTONE DEACETYLASES; HUMANS; INFANT, NEWBORN; MALE; PHENYLBUTYRATES; RNA, MESSENGER; SMN COMPLEX PROTEINS; SPINAL MUSCULAR ATROPHIES OF CHILDHOOD;

EID: 59249089030     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12325-008-0030-1     Document Type: Article

References (18)

1. Pearn J. Classification of spinal muscular atrophies. Lancet. 1980;1:919-922.
2. Crawford TO, Pardo CA. The neurobiology of childhood spinal muscular atrophy. Neurobiol Dis. 1996;3:97-110.
3. Lefebvre S, Bürglen L, Reboullet S, et al. Identification and characterization of the spinal muscular atrophy determining gene. Cell. 1995;80:155-165.
4. Erdem H, Pehlivan S, Topaloǧlu H, et al. Deletion analysis in Turkish patients with spinal muscular atrophy. Brain Dev. 1999;21:86-89.
5. Rodrigues NR, Owen N, Talbot K, et al. Deletions in the survival motor neuron gene on 5q13 in autosomal recessive spinal muscular atrophy. Hum Mol Genet 1995;4:631-634.
6. Burghes AH. When is a deletion not a deletion? When it is converted. Am J Hum Genet. 1997;61:9-15.
7. Lorson CL, Hahnen E, Androphy EJ, et al. A single nucleotide in the SMN gene regulates splicing and is responsible for spinal muscular atrophy. Proc Natl Acad Sci U S A. 1999;96:6307-6311.
8. Chang JG, Hsieh-Li HM, Jong YJ, et al. Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A. 2001;98:9808-9813.
9. Andreassi C, Angelozzi C, Tiziano FD, et al. Phenylbutyrate increases SMN expression in vitro: Relevance for treatment of spinal muscular atrophy. Eur J Hum Genet. 2003;12:1-7.
10. Sumner CJ, Huynh TN, Markowitz JA, et al. Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol. 2003;54:647-654.
11. Brichta L, Hofmann Y, Hahnen E, et al. Valproic acid increases the SMN2 protein level: A well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet. 2003;12:2481-2489.
12. Hahnen E, Eyupoglu IY, Brichta L, et al. In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem. 2006;98:193-202.
13. Riessland M, Brichta L, Hahnen E, et al. The benzamide M344, a novel histone deacetylase inhibitor, significantly increases SMN2 RNA/protein levels in spinal muscular atrophy cells. Hum Genet. 2006;120:101-110.
14. Dover GJ, Brusilow S, Charache S. Induction of fetal hemoglobin production in subjects with sickle cell anemia by oral sodium phenylbutyrate. Blood. 1994;84:339-343.
15. Kleppe S, Mian A, Lee B. Urea cycle disorders. Curr Treat Options Neurol. 2003;5:309-319.
16. Neitzel H. A routine method for the establishment of permanent growing lymphoblastoid cell lines. Hum Genet. 1986;73:320-326.
17. Applied Biosystems. User Bulletin 2: ABI Prism 7700 Sequence Detection System, relative quantitation of gene expression. Foster City, CA: Applied Biosystems; 1997.
18. Barth S, Liss M, Voss MD, et al. Epstein Barr virus nuclear antigen 2 binds via its methylated arginine-glycine repeat to the survival motor neuron protein. J Virol. 2003;77:5008-5013.